DermaSensor Skin Cancer Detection Device

DermaSensor, Inc. is a Miami-based medical device company that makes a handheld device for checking skin lesions for cancer risk in seconds, aimed at primary care physicians as well as dermatologists.

The device uses elastic scattering spectroscopy and a locked AI algorithm, and is indicated for lesions suspicious for melanoma, basal cell carcinoma and squamous cell carcinoma in patients aged 40 and above. It is FDA cleared (De Novo) and CE marked Class IIb, sold in the U.S. and Europe, and used by hundreds of healthcare institutions per its website.

• Spectroscopy sensing: Uses elastic scattering spectroscopy to assess lesions non-invasively.
• Locked AI algorithm: Returns a result indicating whether a lesion needs further care.
• Three cancer types: Covers melanoma, basal cell carcinoma and squamous cell carcinoma.
• Handheld use: Point-and-click device for primary care workflows.
• Reimbursement support: Provides a coding guide and demo programs for U.S. adopters.

General clinics and health-check centers in Vietnam can triage suspicious lesions before dermatology referral. Dermatology chains can standardize first-pass screening. Occupational health teams can screen outdoor workers.

Gives primary care a point-and-click result within seconds, without sending every lesion to a specialist.

Non-invasive optical measurement avoids unnecessary biopsies for low-risk lesions.

Covers all three common skin cancers in one device.

Holds FDA De Novo authorization and a Class IIb CE mark.

Skin cancer is among the most common cancers, and primary care physicians often lack tools to triage lesions. Spectroscopy plus AI devices are entering Europe after U.S. clearance. In Vietnam, general practitioners and aesthetic clinics see many pigmented lesions without dermatoscopy training.

Miami, Florida (per the Sept 2026 press release); founded year not stated. FDA De Novo and CE Class IIb. Germany launch via ContraCare GmbH under the DERMALYTICA brand, plus a feasibility study with the UK NHS on GP use of AI skin cancer assessment.